World's Best Scientists 2026 revealed!
Michele Maio

Michele Maio

D-Index & Metrics

Medicine

D-Index
102
Citations
93345
World Ranking
7466
National Ranking
248

Overview

Michele Maio is affiliated with the University of Siena in Italy and has contributed extensively to research in medicine, particularly focusing on oncology and molecular biology.

Their work spans several key fields and subfields, including:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology
  • Oncology
  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Immunology
  • Cancer Research

The main topics of Maio's research cover:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Epigenetics and DNA Methylation
  • Melanoma and MAPK Pathways
  • Genetic factors in colorectal cancer
  • Colorectal Cancer Treatments and Studies

Among their recent publications are:

  • "Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma," 2022, Zurich Open Repository and Archive (University of Zurich)
  • "Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial," 2020, The Lancet Oncology
  • "Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study," 2022, Journal of Clinical Oncology
  • "Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study," 2022, Annals of Oncology
  • "Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial," 2021, The Lancet Oncology

Frequent coauthors of Maio include:

  • Anna Maria Di Giacomo
  • Alessia Covre
  • Paolo A. Ascierto
  • Luana Calabrò
  • Maria Fortunata Lofiego

The scholar commonly publishes in venues such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • European Journal of Cancer
  • Journal for ImmunoTherapy of Cancer

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Nivolumab in previously untreated melanoma without BRAF mutation.

    Caroline Robert;Georgina V. Long;Benjamin Brady;Caroline Dutriaux

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

    Jedd D. Wolchok;Axel Hoos;Steven O'Day;Jeffrey S. Weber

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

    James Larkin;Paolo A. Ascierto;Brigitte Dréno;Victoria Atkinson

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

    Franck Pagès;Bernhard Mlecnik;Florence Marliot;Gabriela Bindea;Gabriela Bindea;Gabriela Bindea

  • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

    Eugene D. Kwon;Charles G. Drake;Howard I. Scher;Karim Fizazi

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.

    Jérôme Galon;Jérôme Galon;Jérôme Galon;Bernhard Mlecnik;Bernhard Mlecnik;Bernhard Mlecnik;Gabriela Bindea;Gabriela Bindea;Gabriela Bindea;Helen K. Angell;Helen K. Angell;Helen K. Angell

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients

    Mariantonia Logozzi;Angelo De Milito;Luana Lugini;Martina Borghi

  • Cancer classification using the Immunoscore: a worldwide task force

    Jérôme Galon;Franck Pagès;Francesco M Marincola;Francesco M Marincola;Helen K Angell;Helen K Angell

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

Frequent Co-Authors

Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Claus Garbe
Claus Garbe University of Tübingen
Vanna Chiarion-Sileni
Vanna Chiarion-Sileni European Institute of Oncology
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Diana Giannarelli
Diana Giannarelli Sapienza University of Rome
Giorgio Parmiani
Giorgio Parmiani University of Siena
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Caroline Robert
Caroline Robert University of Paris-Saclay
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As the field of medicine continues to evolve, a variety of online degrees are helping students and professionals expand their career options without putting work or life on hold. If you're a registered nurse looking to advance your education, many rn to np bridge programs enable you to earn a Nurse Practitioner qualification online, opening doors to specialized clinical roles.

For those interested in preventative care and wellness, online nutrition degrees provide flexible pathways to enter fields like dietetics, health education, and public health. Similarly, healthcare administration remains a growing area, and completing a cahme accredited online master's program in health administration can prepare you for leadership positions in hospitals, clinics, or public agencies.

If you're seeking a streamlined academic route, some online rn-bsn programs without clinicals allow registered nurses to earn bachelor's degrees efficiently and entirely online. With many roles in healthcare requiring advanced knowledge and credentials, these online programs offer a flexible solution tailored to modern career demands.

Best Scientists Citing Michele Maio

Trending Scientists

Recently Published Articles